Search

everythinglearnresearchcommunity

for

Search:↓

Some breast cancer patients developed permanent hair loss after chemotherapy and hormonal therapy, showing patterns similar to common baldness and alopecia areata.

A woman's hair loss was initially mistaken for a common hair loss condition but was later found to be caused by breast cancer cells in her scalp.

Gemcitabine and paclitaxel are effective and safe as first-line treatment for metastatic breast cancer.

Local hormonal treatment for vulvovaginal atrophy is likely safe for women with estrogen receptor-positive breast cancer on aromatase inhibitors.

No definitive link between finasteride and male breast cancer, but further research is needed.

Oral paclitaxel plus encequidar improved tumor response and caused less neuropathy but more serious infections than intravenous paclitaxel.

Finasteride use may increase the risk of male breast cancer.

Finasteride use is not clearly linked to an increased risk of male breast cancer.

Some breast cancer patients on hormone therapy experience hair loss, and treatments like certain topical inhibitors and supplements may help without harming their cancer prognosis.

Some breast cancer treatments cause hair loss similar to male pattern baldness, which can be improved with minoxidil.

Taking 5-alpha reductase inhibitors does not increase the risk of breast cancer in men.

Patients with metastatic breast cancer treated with epirubicin and docetaxel had a good response and maintained their quality of life.

Some breast cancer treatments, like taxanes, can cause long-term hair loss.

A man developed male breast cancer after four years of finasteride treatment for an enlarged prostate.

Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.

An 86-year-old man with prostate cancer was diagnosed with a rare, low-grade breast cancer and underwent surgery but declined additional hormone therapy.

Understanding breast cancer requires considering both medical advancements and social influences.

Docetaxel and paclitaxel for breast cancer can cause permanent, severe hair loss.

Hair from breast cancer patients shows changes in structure and composition, and a test using these changes detected cancer but also falsely identified some healthy samples as cancerous.

X-ray diffraction of hair might help detect breast cancer non-invasively.

Xiaoaiping reduces chemotherapy side effects and improves quality of life for breast cancer patients.

ADCs can effectively treat breast cancer but may cause side effects like nausea and hair loss.

Certain gene patterns in breast cancer are linked to how active hormone receptors are and could affect patient survival.

Research from 2011 to 2020 shows androgen receptors could be key for prognosis and treatment in certain breast cancers.

Minoxidil and ranolazine together can reduce the spread of certain breast cancer cells.

Electric pulse treatments for breast cancer show promise in being safer and more effective, with fewer side effects.

Some early breast cancer patients have long-term hair loss after chemotherapy, especially older and postmenopausal women.

Enobosarm may effectively treat androgen receptor-positive breast cancer with fewer side effects.

Patients with advanced breast cancer and high hormone receptor levels who had surgery for ovarian/pelvic metastases lived longer, especially if they had high estrogen receptor levels.

Some hormone treatments might raise breast cancer risk, while others don't seem to.